Simultaneous Liver and Kidney Transplantation in a Patient With Telomere Biology Disorder: A Case Study

• Published in: Journal of clinical and experimental hepatology 2024-05, Vol.14 (3), p.101355, Article 101355
• Main Authors: Choudhary, Devprakash, Lekshmon, K.S., Singh, Charanpreet, Subramani, Vanji N., Singh, Yogendra, Mitra, Suvradeep, Sekar, Aravind, Malik, Manaswinee, Bhagat, Naveen, Shiva Kumar, S.P., Taneja, Sunil, Gupta, Vikas, Ramachandran, Raja, Singh, Sarbpreet, Nada, Ritambhra, Kenwar, Deepesh, Duseja, Ajay K., Yadav, T.D., Malhotra, Pankaj, Sharma, Ashish
• Format: Article
• Language: English
• Subjects: combined solid organ transplantation; multi-organ failure; simultaneous liver and kidney transplantation; telomere biology disorder; TINF2 gene mutation
• ISSN: 0973-6883; 2213-3453
• DOI: 10.1016/j.jceh.2024.101355

Organ transplantation is the primary therapy for organ failure caused by telomere biology disorder (TBD). We describe the first documented case of simultaneous liver and kidney transplantation (SLKTx) for TBD, although the diagnosis of TBD was reached only three months following SLKTx. The patient was born prematurely, displayed growth retardation, and developed chronic kidney and liver diseases. His pre-SLKTx autoimmune, metabolic, and viral assessments were negative, and persistent pancytopenia (bone marrow cellularity 70–80%) was attributed to renal disease-associated bone marrow changes. Following SLKTx, he was discharged with stable graft function on tacrolimus and prednisolone. Although mycophenolate mofetil was discontinued on the second postoperative day, his pancytopenia persisted. Despite extensive evaluations, including drug, immune, nutritional, and viral assessments, all results were negative. A bone marrow biopsy conducted three months post-transplant revealed significant hypocellularity (40-50%). Whole genome sequencing revealed a likely pathogenic variant of the TINF2 gene. The patient was subsequently treated with danazol. At the nine-month follow-up post-SLKTx, he exhibited stable graft function and improved cell counts while maintaining triple-drug immunosuppression. Given the lack of uniform diagnostic criteria for TBD, healthcare providers must be vigilant with patients presenting with multi-organ failure and persistent cytopenias. Effective pre-transplant screening for TBD can lead to timely diagnoses, better management, and improved post-transplant outcomes.